Ascendis Pharma A/S
ASND
252.73
-3.23
-1.26%
Ascendis Pharma A/S
US · ASND
#1127 by market cap
Listed 2015
252.73
-3.23
-1.26%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
D
Momentum strategy signal
Hold
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Analyst consensus 20 analysts
Buy
Avg price target 320.00 +26.6%
Price target rangecurrent 252.73
Low274.00
Avg320.00
High356.00
Buy 95%
Hold 5%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-16 | Citi | -- | Buy | 335.00 |
| 2026-11-16 | Barclays | -- | Buy | 341.00 |
| 2026-11-13 | TD Cowen | -- | Buy | 352.00 |
| 2026-11-13 | CCORF | -- | Hold | 274.00 |
| 2026-11-13 | Wells Fargo | -- | Buy | 330.00 |
| 2026-11-13 | UBS | -- | Buy | 315.00 |
| 2026-11-13 | Wedbush | -- | Buy | 346.00 |
| 2026-11-13 | Morgan Stanley | -- | Buy | 302.00 |
| 2026-11-13 | Evercore | -- | Buy | 356.00 |
| 2026-11-13 | Leerink Partners | -- | Buy | 326.00 |
| 2026-11-13 | H.C. Wainwright | -- | Buy | 335.00 |
| 2026-11-13 | Barclays | -- | Buy | 341.00 |
| 2026-11-12 | BofA Securities | -- | Buy | 304.00 |
| 2026-11-12 | RBC Capital | -- | Buy | 290.00 |
| 2026-11-10 | TD Cowen | -- | Buy | 352.00 |
| 2026-11-09 | Morgan Stanley | -- | Buy | 273.00 |
| 2026-11-09 | H.C. Wainwright | -- | Buy | 344.00 |
| 2026-11-02 | Morgan Stanley | -- | Buy | 273.00 |
| 2026-10-26 | CCORF | -- | Hold | 268.00 |
| 2026-10-26 | Morgan Stanley | -- | Buy | 273.00 |
| 2026-10-26 | Citi | -- | Buy | 330.00 |
| 2026-10-23 | Citi | -- | Buy | 330.00 |
| 2026-10-21 | Morgan Stanley | -- | Buy | 273.00 |
| 2026-10-19 | Morgan Stanley | -- | Buy | 273.00 |
| 2026-10-19 | H.C. Wainwright | -- | Buy | 344.00 |
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-12 | -- | ±5.16% | +3.00% (in line) |
| 2026/Q2 | 2026-08-13 | -- | ±6.17% | -3.61% (in line) |
| 2026/Q1 | 2026-05-07 | -- | ±7.59% | +4.34% (in line) |
| 2025/Q4 | 2026-02-11 | After close | ±6.18% | -1.53% (in line) |
| 2025/Q3 | 2025-11-12 | After close | ±8.17% | +3.63% (in line) |
| 2025/Q2 | 2025-08-07 | After close | ±12.00% | +0.60% (in line) |
| 2025/Q1 | 2025-05-01 | After close | ±10.36% | +2.74% (in line) |
| 2024/Q4 | 2025-02-12 | After close | ±7.92% | +12.96% (beat) |
| 2024/Q3 | 2024-11-14 | After close | ±21.02% | +1.79% (in line) |
| 2024/Q2 | 2024-09-03 | After close | ±9.85% | -11.27% (beat) |
| 2024/Q1 | 2024-05-02 | After close | ±21.81% | -2.76% (in line) |
| 2023/Q4 | 2024-02-07 | After close | ±10.41% | -0.03% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Ascendis Pharma A/S discussion 0 comments